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Abstract
Background: Cardiovascular disease (CVD) is the leading cause of adult mortality in low-income countries but data on the
prevalence of cardiovascular risk factors such as hypertension are scarce, especially in sub-Saharan Africa (SSA). This study
aims to assess the prevalence of hypertension and determinants of blood pressure in four SSA populations in rural Nigeria
and Kenya, and urban Namibia and Tanzania.
Methods and Findings: We performed four cross-sectional household surveys in Kwara State, Nigeria; Nandi district, Kenya;
Dar es Salaam, Tanzania and Greater Windhoek, Namibia, between 2009–2011. Representative population-based samples
were drawn in Nigeria and Namibia. The Kenya and Tanzania study populations consisted of specific target groups. Within a
final sample size of 5,500 households, 9,857 non-pregnant adults were eligible for analysis on hypertension. Of those, 7,568
respondents $18 years were included. The primary outcome measure was the prevalence of hypertension in each of the
populations under study.
The age-standardized prevalence of hypertension was 19.3% (95%CI:17.3–21.3) in rural Nigeria, 21.4% (19.8–23.0) in rural
Kenya, 23.7% (21.3–26.2) in urban Tanzania, and 38.0% (35.9–40.1) in urban Namibia. In individuals with hypertension, the
proportion of grade 2 ($160/100 mmHg) or grade 3 hypertension ($180/110 mmHg) ranged from 29.2% (Namibia) to
43.3% (Nigeria). Control of hypertension ranged from 2.6% in Kenya to 17.8% in Namibia. Obesity prevalence (BMI $30)
ranged from 6.1% (Nigeria) to 17.4% (Tanzania) and together with age and gender, BMI independently predicted blood
pressure level in all study populations. Diabetes prevalence ranged from 2.1% (Namibia) to 3.7% (Tanzania).
Conclusion: Hypertension was the most frequently observed risk factor for CVD in both urban and rural communities in SSA
and will contribute to the growing burden of CVD in SSA. Low levels of control of hypertension are alarming. Strengthening
of health care systems in SSA to contain the emerging epidemic of CVD is urgently needed.
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Introduction
Eighty percent of global cardiovascular disease (CVD)
mortality occurs in low- and middle-income countries (LMIC)
[1,2]. According to the World Economic Forum, non-commu-
nicable diseases (NCD), such as CVD, are a severe threat to
global economic development due to the long-term costs of
treatment and the negative effects on productivity [3]. The
burden of NCD is expected to increase substantially in LMIC
and to represent a greater burden of disease compared to
communicable diseases by 2030 [4]. The Unites Nations (UN)
High level meeting on NCDs which took place in September
2011, emphasized the urgent need for greater measures to
prevent and control NCDs in LMIC [5].
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The INTERHEART and INTERSTROKE studies showed
that modifiable risk factors such as hypertension, obesity, smoking,
dyslipidemia and diabetes, account for the majority of CVD in
LMIC [6,7]. Hypertension has been identified as the leading risk
factor for mortality worldwide, and is ranked third as a cause of
disability-adjusted life-years [8]. Hypertension in SSA is believed
to be a problem of the urban areas due to transition to a more
Western lifestyle. Early cross-sectional studies from rural areas in
SSA report low mean blood pressures that are stable with age, and
a low prevalence of hypertension [9,10,11,12,13]. Migration
studies in LMIC showed that migrants from rural to urban areas
showed an increase in blood pressure [14,15]. Recent studies from
rural areas in SSA suggest that the prevalence of hypertension is
increasing in rural populations. However, unrelated studies are
difficult to compare due to a lack of age- standardized prevalence
data [16,17,18,19]. Hypertension prevalence data are crucial for
understanding the magnitude of the problem, identifying groups at
high risk for CVD, and evaluating the effects of policy and practice
interventions [20]. However, hypertension prevalence data for
SSA are scarce [21,22]. This study describes the prevalence of
hypertension and the determinants of increasing blood pressure in
4 SSA populations in rural Nigeria and Kenya and in urban
Namibia and Tanzania.
Methods
Ethical clearance
Ethical clearance for the study reported in this paper was
obtained from the Ethical Review Committee of the University of
Ilorin Teaching Hospital in Nigeria; the Research Ethics
Committee at the Ministry of Health and Social Services in
Namibia; the National Institute for Medical Research and the
Tanzania Commission for Science and Technology in Tanzania,
and the Institutional Research and Ethics Committee from Moi
Teaching and Referral hospital/Moi University in Kenya. Written
informed consent was asked for participation in the blood tests by
signature or fingerprint. A standard operating procedure for verbal
informed consent was followed for the questionnaire and
anthropometrics according to local standard practice for partic-
ipation in observational studies. Interviewers recorded the
outcome of the consent procedure on behalf of the participant.
This procedure was approved by the ethical committees and
review boards in all four countries.
Study design and study populations
For this study we included data from four cross-sectional
household surveys. The survey in rural Nigeria included a
representative, population-based sample of Afon and Ajasse Ipo
district in Kwara State. Data were collected in 2009. The survey in
rural Kenya included a sample of a specific target group composed
of members of dairy farmer cooperatives and their families in the
Nandi district. Data were collected in 2011. The survey in urban
Tanzania included members of a microcredit organization and
their families in Dar es Salaam. Data were collected in 2010. The
Namibian survey included a representative sample of the
population of Greater Windhoek. The data from Namibia were
collected during a survey in 2009 in which households included in
a previous survey in 2006, when blood pressure data were not
collected, were revisited. Therefore, only the data from the 2009
survey are included in this analysis.
All surveys were carried out as part of an evaluation of the
impact of affordable private health insurance schemes [23,24] on
socioeconomic and medical parameters. The surveys in Nigeria,
Kenya and Tanzania served as baseline surveys before the
insurance scheme was implemented. The Namibian study
population had access to a comparatively well-developed market
for health insurance [25]. All study populations consisted of
private households eligible for the insurance program and similar
control populations, excluding household members who at the
moment of the visit resided in hospitals, hostels and prisons. Only
the adult, non-pregnant population was included in the analysis
because hypertension is rare in children and because pregnancy-
related hypertension has a different etiology.
Sampling
Nigeria: Stratified random samples were drawn by random-
ization of geographical areas. A two-staged probability sample was
drawn. The first stage consisted of randomly selecting 100 out of
300 enumeration areas (EAs) from the 2005 National Population
Census within 15 kilometres distance from three towns: Afon,
Aboto Oja - the two towns where the insurance program clinics
are based - and Ajasse Ipo. Henceforth, Afon and Aboto Oja are
considered treatment area, and Ajasse Ipo control area. In both
areas, the sample was stratified based on whether the EA was in or
outside this town to allow for sufficient households from remote
areas with more difficult access to care. In the ‘‘treatment area’’,
the insurance program will be offered, in the control area, the
insurance program will not be rolled out within the next three
years. In the second stage, households were sampled weighted on
EA size such that the sample represented the population density.
Kenya: A random sample of households was drawn from the
member list of the dairy farming cooperation that was eligible for
the insurance program. The same procedure was followed for the
control group, another dairy farming cooperation with similar
socio-economic and geographic characteristics who will not be
eligible for the insurance program in the coming years.
Tanzania: A sample was drawn from the microcredit branch
that was eligible for the insurance program using a member list.
Out of 159 Market Enterprise Committees (MECs) with a total of
2613 clients, 55 MECs were randomly selected, plus an additional
23 MECs to accommodate possible non-response and refusals. In
each MEC, 5 Enterprise groups (EGs) were randomly selected and
all group members were included in the treatment sample. A
similar branch that was not eligible for the insurance program was
used as a control group. A propensity score weighted sample of 55
MECs was drawn from the control branch, in which MECs with
similar characteristics as those in the ‘‘treatment’’ branch were
more likely to be selected. Weights were determined based on a
logit estimation of being in the treatment group. Again 5 EGs were
randomly sampled from the selected MECs, and all group
members were included in the sample. In total, this resulted in a
sample of 1790 clients.
Namibia: The survey was conducted among a representative,
self-weighted sample of the Greater Windhoek population of
Namibia in 2006 using the national sampling frame from the
Central Bureau of Statistics in Namibia. In the first stage, 100
Primary Sampling Units (PSUs) were selected proportional to
population size. PSU selection was done in proportion to the
number of households per cluster from the Census 2001. In the
second stage, 20 households per PSU were selected, based on the
lists from a household identification exercise. A more detailed
description of the survey design and sampling methods is described
elsewhere [26]. In 2009, the same households were traced and
revisited.
Sample Size
The sample size for all surveys was determined based on
socioeconomic outcome measures defined to study the impact of
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the insurance program on socioeconomic status. Outcome
measures included health care utilization and medical expenses,
household assets and household consumption. The main objective
of this sub-study, to describe the prevalence of hypertension, was a
secondary objective of the four household surveys. Therefore, no
formal sample size calculations were performed using the
prevalence of hypertension as main outcome measure. However,
the sample size in all surveys provides sufficient power to allow for
reliable estimations of hypertension prevalence. For example,
power to detect a difference in hypertension prevalence across the
age groups used in this analysis was 99% in all surveys.
The target sample size was 1500 households in Nigeria, 1200
households in Kenya, 800 households in Tanzania and 2000
households in Namibia.
Data collection
The methodology of all surveys was based on the World Bank
Living Standards Measurements Surveys methodology [27]. Face-
to-face questionnaires were administered by trained interviewers
recruited from the local universities.
The questionnaire collected demographic, socioeconomic and
medical information. Annual household consumption was mea-
sured to investigate household socioeconomic status and welfare.
Food consumption was measured over the past 7 days, frequent
non-food consumption over the past month, and non-frequent
non-food consumption over the past year. The consumption score
was constructed by summing food consumption (526), frequent
non-food consumption (126), and non-frequent non-food con-
sumption in each household [27]. Annual per capita consumption
was calculated as annual household consumption divided by the
number of household members. Local currencies were converted
to purchasing power parity (PPP) corrected USD to facilitate
comparison across countries using the 2009 World Bank
conversion factors [28].
Body weight, height, waist circumference and blood pressure
measurements, and a finger prick (venepuncture in Kenya) for
blood testing (glucose, cholesterol, HIV, hemoglobin [Hb]) were
performed using standardized methods. Blood pressure was
measured three times on the upper left arm after at least 5 minutes
of rest using a validated automatic blood pressure device (Nigeria,
Kenya, Tanzania: OMRON M6 Comfort, OMRON Corpora-
tion; Namibia: Rossmax MG 150F, Taiwan). The mean value of
the 2nd and 3rd measurement was used for analysis. Weight was
measured using validated digital scales (OMRON BF400,
OMRON Cooperation; SECA 813, SECA 803, SECA, Ger-
many). Height was measured using SECA portable stadiometers
(SECA Germany).
Respondents were asked about their fasting state. Glucose and
cholesterol were measured using the following tests. Nigeria and
Tanzania: Glucose Whole Blood-OneTouch UltraEasy Monitor-
ing System, Lifescan (Johnson & Johnson company, USA);
Namibia: Roche Accutrend GCT and Accutrend Plus Glucose
and Cholesterol (Roche Germany); Kenya: Cobas integra 400 plus
Chemistry analyzer (Roche Germany). Hemoglobine in Nigeria
and Tanzania was measured using Hemocue Whole Blood
Hemoglobin Systems (Hemocue, Sweden) and Beckman Coulter
AcT 5 Diff Hematology Analyzer (Beckman Coulter Inc, USA) in
Kenya. HIV screening was done using the following tests. Nigeria/
Kenya: Determine HIV-1/2, (Abbott Japan CO., LTD); Tanza-
nia: SD Bioline HIV 1/2 (SD Standard Diagnostics Inc); Nambia:
OraSureH 107 HIV-1 Oral Specimen Collection Device (OraSure
Technologies, Inc., Bethlehem, PA), HIV tests: Oral Fluid
Vironostika HIV Uni-Form II Micro-ELISA (bioMe´rieux111
Inc., Durham, NC).
Revisits: Households were revisited at least once in all surveys
in case household members were not present or in case the
interview was not completed during the first visit. In Namibia,
households that had relocated their residence between 2006 and
2009 were traced within Greater Windhoek wherever possible. In
Kenya, only households in which all household members were
absent were revisited.
Statistical methods
Definitions: Hypertension was defined as a measured blood
pressure $140 mmHg systolic and/or $90 mmHg diastolic, or
self-reported use of drug treatment for hypertension irrespective of
measured blood pressure [29].
Isolated hypertension was defined as a blood pressure of
$140 mmHg systolic and ,90 mmHg diastolic. Isolated diastolic
hypertension was defined as a diastolic blood pressure
$90 mmHg and systolic blood pressure ,140 mmHg.
Awareness of hypertension was defined as respondents who self
report to have hypertension.
Treatment for hypertension was defined respondents who self
report to have hypertension, and who indicate to take drug
treatment for hypertension.
Controlled hypertension was defined as respondents who self
report to have hypertension, and who have a blood pressure below
140 mmHg systolic and 90 mmHg diastolic.
For 32 (1.8%) respondents who reported hypertension, treatment
status was unknown because they had more than 1 chronic disease
(for example diabetes and hypertension) and treatment status was
only asked for one condition. We considered these respondents as on
treatment since this is most likely if they report the diagnosis and
receive treatment for another chronic disease.
Diabetes mellitus was defined as the presence of a non-fasting
blood glucose of $11.1 mmol/L, or a fasting blood glucose of
$7.0 mmol/L, or self reported use of drug treatment for diabetes
[30].
Cholesterol was classified based on the Adult Treatment Panel III
classification [31] with high cholesterol defined as $6.2 mmol/L.
Data analysis: Data were analyzed using STATA, version
10.0 (StataCorp LP, Texas, USA). The prevalence of hypertension
and other CVD risk factors was explored using descriptive
statistics. Age-standardized prevalence of hypertension was
calculated using the WHO New World Reference Population
[32]. Age-standardization is necessary when comparing popula-
tions given possible differences in the underlying age structure
between populations, as well as the strong associating of age with
the risk of disease [33]. Although no formal statistical comparison
of the hypertension prevalence across the four surveys were
performed, age-standardized prevalence rates are provided to
allow for comparison with other studies [16].
Ten year CVD risk based on age, gender, blood pressure,
diabetes and smoking status was calculated using WHO risk charts
for patients $40 years of age [34].
Multivariable linear regression analyses were performed to
assess the association of well-known predictors for hypertension
with blood pressure. Variables included in the analysis were sex,
age, body mass index (BMI) and socioeconomic status (measured
as consumption, i.e. household foods and non-food expenditures),
regardless of statistical significance. In addition, HIV status and
Hb were tested because of possible relevance in this setting
[35,36,37] and were included in the model where significant at a
p-value of 0.05. Plausible interactions were explored to assess
whether specific combinations of variables modified the risk for
increasing blood pressure. In Namibia and Nigeria, estimates were
corrected for clustering at the primary sample unit level.
Hypertension in Sub-Saharan Africa
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In a second step, the regression models for each population were
expanded with additional variables to evaluate if there was
clustering of high blood pressure with other risk factors for CVD.
Variables included were waist circumference, presence of diabetes,
smoking, alcohol use, family history of CVD, blood cholesterol
levels and low fruit and vegetable intake. In addition, the
association of possible context-specific relevant socioeconomic
variables with blood pressure was explored. Variables tested
include education, religion and insurance status. Variables
included in the final model were significant at a p-value of 0.05.
Respondents without any blood pressure measurement were
excluded from the main analysis. A sensitivity analysis was
performed to estimate the bias due to non-random missing data.
In this analysis, regression models that included age and gender
were used to predict the presence of hypertension in respondents
without a blood pressure measurement. These imputed values for
hypertension presence were used to recalculate the prevalence of
hypertension.
Results
Population characteristics
The number of sampled households, the number of households
and individuals who participated, and reasons for non participa-
tion are shown in Figure 1.
The characteristics of the study populations are shown in
Table 1. The proportion of males in the sample ranged from
40.1% in Kenya to 46.6% in Nigeria. The mean age distribution
of the populations ranged from 36.8 years in Tanzania to 45.3 in
Nigeria. The Nigerian respondents mainly belonged to the Yoruba
ethnic group (83.2%), the majority of the Kenyan study population
consisted of Kalenjin (98.6%). Ethnicity was not asked explicitly in
Tanzania and Namibia. However, 83.4% of the Namibian
respondents report an indigenous African language as first
language which could be used as a proxy to black ethnicity. Only
5 (0.29%) respondents reported German as first language, a proxy
for Caucasian descent. The populations were predominantly
Muslim in Nigeria (79.4%) and Tanzania (66.3%), and Christian
in Kenya (93.4%) and Namibia (98.8%). Education levels were
low, especially in the population in Nigeria where .50% of
respondents did not complete primary school. Socioeconomic
status, measured as per capita annual food and non-food
consumption (in PPP corrected USD) was lowest in the Nigerian
study population (which was a rural population) and highest in
Namibia (an urban population). The variance in consumption
level was low in all populations, except for Namibia, as can be
expected in rural communities or specific targets groups.
Individual insurance coverage of any type of health insurance
was low in Nigeria (0.8%) and Tanzania (1.9%). The Namibian
sample showed higher coverage levels (26.0%). The Namibian
Figure 1. Participation in the 4 surveys (household and individual level). *HH = households, **Repeating sampling done because
household were difficult to locate due to poor registries used for sampling, {BP= blood pressure.
doi:10.1371/journal.pone.0032638.g001
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study population had access to a comparatively well-developed
market for health insurance [25]. Information on individual health
insurance coverage was not available for the Kenyan study
population, but 14.8% of the households reported to have at least
1 household member insured.
Prevalence of hypertension and other CVD risk factors
Hypertension was the most prevalent risk factor for CVD in all
four populations. The crude prevalence of hypertension ranged
from 19.0% in Tanzania to 32.0% in Namibia (Table 2). The age-
adjusted prevalence was 19.3% in Nigeria, 21.4% in Kenya,
23.7% in Tanzania and 38.0% in Namibia (Figure 2A). The
prevalence of hypertension increased with age (Figure 2A). Within
the hypertensive population, the proportion of individuals with
grade 2 ($160/100 mmHg) or grade 3 hypertension ($180/
110 mmHg) (Figure 2B) ranged from 29.2% in Namibia to 43.3%
in Nigeria. Mean systolic blood pressure ranged from 121.6 to
123.8 mmHg, mean diastolic blood pressure ranged from 78.1 to
80.2 mmHg. Mean systolic blood pressure in those with
hypertension ranged from 142.8 mmHg in Namibia, where the
highest treatment rates were found, to 155.6 mmHg in Nigeria
(lowest treatment rate). Mean diastolic blood pressure in those with
hypertension ranged from 94.3 mmHg in Namibia to 98.2 mmHg
in Tanzania. The majority of the hypertensive population had
both systolic and diastolic hypertension in all study populations
(Table 2). Hypertensive respondents younger than 45 years had
predominately diastolic hypertension, whereas the majority of the
respondents older than 45 years had both systolic and diastolic
hypertension. The proportion of respondents with isolated systolic
hypertension increased with age (Figure S1).
Sensitivity analyses were performed to estimate the bias due to
non-response and loss to follow up on hypertension prevalence in
Kenya and Namibia respectively. A prediction model that
included age and gender was used to predict the prevalence of
hypertension in case of 100% response and 100% follow up. This
analysis showed an estimated prevalence of hypertension of 17.3%
(95%CI 16.8–17.8) in Kenya, compared to an observed crude
prevalence of 20.2% and an estimated prevalence of 27.8% (27.3–
28.3) in Namibia, compared to an observed crude prevalence of
32.0%.
The proportions of respondents with hypertension who were
aware of their condition, who reported to be on anti-hypertensive
treatment, and whose blood pressure was controlled are shown in
Figure 3. The proportions of respondents with hypertension on
treatment ranged from 7% in those with grade 1 hypertension to
17.5% in those with grade 3 hypertension. Treatment proportion
did not increase with hypertension severity in the Nigerian study
population, where the overall treatment proportion was very low
(data not shown). Hypertension control was lowest in Kenya
(2.6%) and highest in Namibia (17.8%). Respondents who were
insured in Namibia showed better hypertension control (Figure
S2).
The prevalence of other CVD risk factors was lower compared
to the prevalence of hypertension. Obesity prevalence ranged from
6.1% (Nigeria) to 17.4% (Tanzania). Diabetes prevalence was
lowest in Namibia (2.1%) and highest in Tanzania (3.7%).
Smoking prevalence ranged from 4.1% (Tanzania) to 13.5%
(Namibia). Hypercholesterolemia prevalence was 2.7% in Namib-
ia and 4.8% in Kenya (Table 2).
Risk factors for hypertension
In all populations, age and BMI were independent predictors
for increasing blood pressure (Table S1A–D). The effects of
increasing age and BMI on blood pressure were different for men
and women. Therefore, the effects are reported separately.
Women had a steeper increase in blood pressure with increase
in age compared to males, while males had a steeper increase in
blood pressure with higher BMI. In Namibia, respondents with
lower socioeconomic status (lower consumption in USD PPP) had
higher blood pressure. Hb concentrations and HIV status were
tested because of possible associations with blood pressure and
CVD respectively [35,36,37]. Hb concentrations were measured
Table 1. Characteristics of the study populations.
Rural Nigeria Rural Kenya Urban Tanzania Urban Namibia
N N N N
Male, n (%) 2678 1247(46.6) 2111 847 (40.1) 1046 423 (40.4) 1733 771 (44.5)
Age (Years), mean (SD) 2678 45.3 (18.3) 2109 40.9 (16.2) 1046 36.8 (11.2) 1716 36.9 (13.4)
Age , n (%) 2678 2109 1046 1716
18–24 392 (14.6) 341 (16.2) 143 (13.7) 378 (22.0)
25–34 456 (17.0) 511 (24.2) 328 (31.4) 431 (25.1)
35–44 445 (16.6) 509 (24.1) 340 (32.5) 435 (25.3)
45–54 505 (18.9) 332 (15.7) 164 (15.7) 270 (15.7)
$55 880 (32.9) 416 (19.7) 71 (6.8) 202 (11.8)
Level of education, n (%) 2446 2091 996 1559
, primary 1457 (59.6) 414 (19.8) 76 (7.6) 302 (19.4)
primary 449 (18.4) 826 (39.5) 685 (68.8) 445 (28.5)
secondary 340 (13.9) 645 (30.8) 202 (20.3) 691 (44.3)
tertiary 200 (8.2) 206 (9.9) 33 (3.3) 121 (7.8)
Consumption*, mean (SD) 2677 1271.7 (1131.4) 2111 1925.9(2624.8) 1044 3791.6 (2803.0) 1731 4932.0 (9221.5)
Currently insured, n (%) 2678 21 (0.8) NP{ 1011 19 (1.9) 1725 448 (26.0)
{NP = Not Performed;
*Consumption per capita per year in USD corrected for purchasing power parity (PPP), 2009 conversion rate World bank (http://www.worldbank.org/).
doi:10.1371/journal.pone.0032638.t001
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in the surveys in Nigeria, Tanzania and Kenya and showed a wide
range from 3.6 mmol/L to 13.4 mmol/L. Respondents with Hb
in the lowest tertile (by country and gender) had lower blood
pressure in Nigeria and Kenya. No association between blood
pressure and HIV status was found.
The regression models were expanded to explore associations
between increasing blood pressure and other CVD risk factors
(Table S1A–D). Respondents with high blood pressure were more
likely to have other CVD risk factors such as higher cholesterol
and larger waist circumference. Smoking was not associated with
blood pressure in any of the study populations but the proportion
of smokers was low in general (Table 2). An association between
blood glucose levels suspected for diabetes and high blood pressure
was only found in the Nigerian population.
In all analyses, adjusting for clustering at household level did not
result in significantly different effects (data not shown).
Discussion
The scale of the surveys described in this study is unique,
demonstrating the magnitude of the problem of hypertension in
different countries in SSA, including rural and urban areas. The
Figure 2. Hypertension prevalence and distribution of blood pressure. 2A: Age-standardized and age stratified hypertension prevalence. 2B:
Distribution of blood pressure in patients with hypertension (treated and untreated cases). Optimal = systolic blood pressure (SBP) ,120 and
diastolic blood pressure (DBP) ,80; Normal = SBP 120–129 and/or DBP 80–84; Pre-HT (hypertension) = SBP 130–139 and/or DBP 85–89; Grade 1 =
SBP 140–159 and/or DBP 90–99; Grade 2 = SBP 160–179 and/or DBP 100–109; Grade 3 = SBP.= 180 and/or DBP.=110.
doi:10.1371/journal.pone.0032638.g002
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four populations are very different in terms of socioeconomic
status, living environment and geographical location. Yet,
hypertension was the most frequently observed risk factor for
CVD and determinants for blood pressure were similar, in all four
populations. The prevalence of hypertension observed in our
survey in the Greater Windhoek area in Namibia was remarkably
high (crude 32%, age-standardized 38%). This prevalence is
similar to the prevalence of hypertension in adults in the USA
where an overall prevalence of 31% in adults and 38.6% in non-
Hispanic blacks was reported [38]. The prevalence of hyperten-
sion in rural Nigeria is lower compared to in high income
countries or in other parts of SSA [16,39], as can be expected in a
rural community where people are more likely to follow a
traditional African lifestyle. However, both mean blood pressures
and the prevalence of hypertension in the Nigerian study
population were much higher compared to early studies in rural
populations in SSA [40,41,42,43,44,45]. The rapid changes
towards a more Western lifestyle that are taking place in LMIC
is likely to contribute to an increase in the prevalence of
hypertension in the coming years, in both rural and urban areas
[46]. Whereas mean systolic blood pressure is decreasing since
1980 in high income countries, trends in blood pressure show an
increase in systolic blood pressure in many SSA regions and mean
systolic blood pressures in SSA are amongst the highest in the
world [21]. In addition, people of black African origin have been
identified as having a higher risk of target organ damage
Table 2. Prevalence of Hypertension and other CVD risk factors.
Rural Nigeria Rural Kenya Urban Tanzania Urban Namibia
N N N N
HT* (crude), n (%) 2678 563 (21.0) 2111 426 (20.2) 1046 199 (19.0) 1733 555 (32.0)
Isolated systolic HT{, n (%) 547 113 (20.7) 415 60 (14.5) 190 24 (12.6) 456 59 (12.9)
Isolated diastolic HT{, n (%) 547 102 (18.7) 415 164 (39.5) 190 70 (36.8) 456 155 (14.0)
WHO CVD risk $20% (age $40)", n (%) 1603 79 (4.9) 984 24 (2.4) 380 7 (1.8) 688 17 (2.5)
Eligible for HT drug treatment WHO"", n (%) 2667 244 (9.2) 2090 138 (6.6) 1032 78 (7.6) 1715 162 (9.5)
SBP** (mmHg) , mean (SD) 2678 122.3(22.5) 2111 121.6 (18.3) 1046 123.3(17.6) 1733 123.8 (20.2)
DBP**(mmHg), mean (SD) 2678 78.1 (13.0) 2111 79.9 (11.7) 1046 79.6 (12.4) 1733 80.2 (14.6)
SBP in HT patients (mmHg) , mean(SD) 563 155.6 (22.3) 426 146.4 (20.8) 199 148.1 (19.4) 555 142.8 (21.0)
DBP in HT patients(mmHg), mean (SD) 563 96.8 (11.7) 426 96.4 (10.6) 199 98.2 (11.4) 555 94.3 (13.5)
Heart rate (bpm) in those with HT, mean (SD) 563 78.3 (13.2) 424 74.4 (12.0) 199 83.0 (13.7) NPI|
BMI{{ (kg/m3), mean (SD) 2618 22.4 (4.3) 2059 23.2 (4.7) 990 25.8 (4.9) 1710 24.9 (5.4)
BMI classification, n (%) 2618 2059 990 1710
Overweight (.25) 413 (15.8) 433 (21.0) 344 (34.7) 444 (26.0)
Obese (.30) 160 (6.1) 195 (9.5) 172 (17.4) 290 (17.0)
WC M{ (cm), mean (SD) 1232 78.9 (10.4) 796 78.8 (13.0) 420 83.6 (12.3) 769 79.3 (13.1)
WC F (cm), mean (SD) 1392 82.6 (13.4) 1231 81.4 (14.7) 615 85.5 (14.4) 953 82.9 (15.4)
Abdominal obese1, n (%) 2624 410 (15.6) 2027 399 (19.7) 1035 254 (24.5) 1722 341 (19.8)
DMI, n (%) 1761 51 (2.9) 1331 34 (2.6) 566 21 (3.7) 1652 34 (2.1)
Glucose (mmol/L), mean (SD) 1760 5.0 (2.2) 1316 5.0 (1.4) 559 4.9 (2.1) 1651 5.4 (1.3)
Cholesterol, mean (SD) NP 1336 4.4 (1.1) NP 1714 4.4 (0.7)
High Cholesterol1, n (%) NP 1336 64 (4.8) NP 1714 47 (2.7)
HIV positive 1772 50 (2.8) 1329 42 (3.2) 538 80 (14.9) 1679 280 (16.7)
Hb (mmol/L), mean (SD) 1762 8.2 (1.4) 1339 9.0 (1.4) 539 7.8 (1.4) NP
Smoking, n (%) 2669 277 (10.4) 2094 97 (4.6) 1040 43 (4.1) 1733 234 (13.5)
Alcohol .2 U/day11, n (%) 2670 4 (0.1) 2073 29 (1.4) 1033 5 (0.5) 1729 54 (3.1)
Reported diagnosis of HT, n (%) 2674 49 (1.8) 2098 84 (4.0) 1023 38 (3.7) 1733 215 (12.4)
Family History HT, DM, heart disease***, n (%) 2678 99 (3.7) 2111 319 (15.1) 1046 203 (19.4) 1733 615 (5.5)
*HT = hypertension;
{In those with untreated or inadequately treated hypertension;
"WHO CVD risk charts start at age 40 years and older;
""Those with blood pressure $160/100 mmHg or 140/90 and 10 year CVD risk of $20%;
**SBP = systolic blood pressure, DBP = diastolic blood pressure;
I|NP = not performed;
{{BMI = Body Mass Index;
{WC = waist circumference, M = male, F = female;
&parDM =Diabetes Mellitus (non-fasting blood glucose of $11.1 mmol/L, or a fasting blood glucose of $7.0 mmol/L, or self reported use of drug treatment for DM);
1High cholesterol $6.2 mmol/L;
11U=1 standard unit of alcohol containing approximately 10 g of ethanol;
***Reported parent with hypertension, diabetes or heart disease.
doi:10.1371/journal.pone.0032638.t002
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compared to Caucasians for a given blood pressure [47,48,49,50]
and the onset of CVD in LMIC countries occurs at an earlier age
compared to high income countries [39]. Finally, even though the
prevalence of hypertension in SSA is still lower compared to the
high income regions, the large and growing population of LMIC
such as Nigeria will result in a considerably larger absolute number
of individuals affected compared to high income countries [39,51].
A recent study in rural Kenya found a similar prevalence of
hypertension [52] as our study whilst surveys in urban Tanzania
found a higher prevalence [16]. The Tanzanian and Kenyan study
populations in our surveys consisted of individuals and their
household members, participating in a microcredit program and
in a dairy cooperative respectively. These specific characteristics
preclude generalization of our conclusions regarding the preva-
lence of hypertension to the general urban population of Tanzania
or the rural population of Kenya. Previous research showed large
regional differences in hypertension prevalence in SSA, depending
on the level of urbanization and other environmental and possibly
genetic factors, although the available data is limited [16,19,22].
Therefore, our surveys are not representative for the whole
continent of Africa but should be regarded as a contribution to
filling the gaps in knowledge on regional prevalence data.
The prevalence of hypertension was based on three measure-
ments of blood pressure on one occasion in this study. In clinical
practice, a diagnosis of hypertension requires multiple measure-
ments on several occasions. Therefore, the prevalence of
hypertension found in our surveys might be an overestimation,
although the normal mean heart rate did not support high blood
pressure readings due to sympathic activation. Our study does not
allow differentiating between primary and secondary hyperten-
sion. To the best of our knowledge, there are no data available on
the prevalence of secondary hypertension and the underlying
causes in the population from SSA.
Early identification and treatment of people with hypertension
is vital. The proportion of respondents with hypertension on
treatment was low in Nigeria, Kenya and Tanzania. The
proportion on treatment increased with more severe hypertension.
Blood pressure control as low as 2.6% (Kenya) is of concern and in
line with previous findings from SSA [16,52,53,54,55,56,57,58].
Poor access to health care, in particular availability and
affordability of drugs and travel costs, are barriers to CVD
prevention treatment in LMIC. There is an ongoing debate about
whether limited funds in LMIC should be spent on NCDs if the
burden of communicable diseases is still high [59]. Lifestyle
interventions such as salt reduction or weight loss are cheap
interventions that might be cost saving [60]. These lifestyle
interventions are reported to reduce blood pressure with 3–
4 mmHg systolic and 2–3 mmHg diastolic [61,62]. In our study,
between 29.2% (Namibia) and 43.3% (Nigeria) of the respondents
with hypertension had grade 2 or grade 3 hypertension.
Therefore, our data show that a large proportion of the patients
with hypertension may not be adequately treated with lifestyle
interventions only. In these groups, drug treatment will be
necessary to achieve target goals. Individual (drug) interventions
for CVD prevention for high risk groups are available and were
shown costs effective in modeling studies [60]. Calculation of total
absolute CVD risk according to WHO risk charts did not contribute
to identification of respondents eligible for antihypertensive drug
Figure 3. Awareness, treatment and blood pressure control in patients with hypertension. Definitions: Aware = respondents who self
report to have hypertension, Treated = respondents who self report to have hypertension, and who indicate to take drug treatment for
hypertension, Controlled = respondents who self report to have hypertension, and who have a blood pressure below 140/90 (patients who use drug
treatment or for whom treatment status is unknown).
doi:10.1371/journal.pone.0032638.g003
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treatment other than those with high blood pressure. WHO
classifies individuals with blood pressure at or above 140 mmHg
systolic or 90 mmHg diastolic eligible for treatment if 10 year
CVD risk is $20%. Individuals with blood pressure 160 mmHg
systolic or 100 mmHg diastolic are eligible for treatment
regardless of other risk factors [34]. Due to the low prevalence
of diabetes and smoking, treatment eligibility was entirely driven
by blood pressure. However, respondents with higher blood
pressure were more likely to have other CVD risk factors such
as high cholesterol, larger waist circumference and diabetes
(Table S1A–D). This clustering of risk factors is important as it
increases a persons’ overall CVD risk.
Our surveys have all been conducted as part of an evaluation to
assess the impact of private health insurance schemes for low and
middle income groups in SSA. There is increasing advocacy for
affordable health insurance schemes as part of a broader solution
to health care financing problems in LMIC [63,64,65]. Health
insurance may be helpful to improve access to care, especially for
patients with chronic conditions such as hypertension. Strength-
ening of current health systems and improving access to care for
patients in LMIC is essential and was recently recommended in
the UN declaration resulting from the UN High-Level Meeting on
Non-Communicable Diseases [5]. Our data from Namibia showed
that treatment and control rates for hypertension were higher for
those insured, although no conclusion about improved access to
care can be drawn based on these data as people with
hypertension might be more likely to enroll in insurance schemes.
We conclude that hypertension is the most frequently observed
CVD risk factor in both urban and rural communities in multiple
regions in SSA. The prevalence is expected to increase in the
coming years. The determinants of blood pressure were consistent
in all study populations and similar to described in other
populations. Low levels of awareness, treatment and control of
hypertension are alarming and may reflect poor access to care.
Strengthening of health care systems in SSA to contain the
emerging epidemic of CVD is urgently needed.
Supporting Information
Figure S1 Blood pressure pattern per age group in
respondents with untreated or inadequately treated
hypertension, all countries combined. HT = Hyperten-
sion, Isolated systolic hypertension = systolic blood pressure$140
and diastolic blood pressure ,90, Isolated diastolic hypertension
= diastolic blood pressure $90 and systolic blood pressure ,140.
(TIF)
Figure S2 Awareness, treatment and blood pressure
control in patients with hypertension in Namibia:
insured versus not insured. Definitions: Aware = respon-
dents who self report to have hypertension, Treated =
respondents who self report to have hypertension, and who
indicate to take drug treatment for hypertension, Controlled =
respondents who self report to have hypertension, and who have a
blood pressure below 140/90 (patients who use drug treatment or
for whom treatment status is unknown).
(TIF)
Table S1 Multivariable prediction models for blood
pressure. SBP = systolic blood pressure, DBP = diastolic blood
pressure, CI = confidence interval, Robust CI in parentheses, NP
= not performed. Age = per year older, BMI = per unit
increase, waist = per cm increase, cholesterol = per mmol/L
increase *Compared to Hb tertile 1, **Food and non food
consumption in log(USD/1000), "Compared to patients without
diabetes, 1Compared to no alcohol use, Iper piece increase per
week, IIPer serving increase per week. Table S1A Step 1:
Estimates corrected for ethnic group. Step 2: Estimates corrected
for age, gender, BMI, Hb tertile and ethnic group. Table S1B Step
2: Estimates corrected for age, gender, BMI and Hb tertile. Table
S1C Step 1 and 2: Estimates corrected for age, gender and BMI
Table S1D Step 1: Estimates corrected for ethnic group (language
used as proxy). Step 2: Estimates corrected for age, gender, BMI,
consumption and ethic group (language used as proxy). Note:
Smoking status, family history CVD, education, religion, insur-
ance status, HIV status not significant in any of the study
populations (at a p value of 0.05) and excluded from all models.
Hemoglobine levels not available for Namibia, cholesterol levels
only available for Kenya and Namibia, data on fruit and vegetable
intake only available for Tanzania and Kenya.
(DOC)
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